T. Rowe Price Investment Management Reports New 6.7% Stake in Kymera Therapeutics Inc

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting a new significant ownership position in Kymera Therapeutics Inc (KYMR). As of the event date on March 31, 2026, the investment adviser beneficially owns 5,460,257 shares of common stock, representing a 6.7% stake in the company. This filing marks an increase from a previous 0.0% holding, establishing T. Rowe Price as a major institutional shareholder. Of the total shares held, the filer reports sole voting power over 5,318,875 shares and sole dispositive power over the full 5,460,257 shares. The filing was made under Rule 13d-1(b), indicating that the securities were acquired in the ordinary course of business and not with the intent to influence or change the control of the issuer. Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts. The filing was officially signed by Ellen York, Vice President of T. Rowe Price Investment Management, on May 15, 2026.